The use of dipyridamole to wean from inhaled nitric oxide in congenital diaphragmatic hernia.
A full-term neonate with a left-sided congenital diaphragmatic hernia (CDH) was ventilated mechanically by high-frequency oscillatory ventilation (HFOV). Despite inhaled nitric oxide (iNO) at a dose of 15 ppm, the neonate had severe respiratory acidosis and was placed on extracorporeal membrane oxygenation (ECMO) for 2 days. On day 7 of life, surgical repair of the CDH was performed. After the intervention, iNO (20 ppm) had to be restarted because of severe pulmonary hypertension (PHT). Ventilatory support and iNO then were weaned progressively. However, each daily attempt to discontinue iNO (from 2 ppm to 0 ppm), led to severe desaturation with significant right-to-left shunting. At the age of 33 days, dipyridamole (persantin) was administered intravenously at a dose of 0,4 mg/kg/min over 10 minutes and repeated every 12 hours for a total of 3 doses. After the second administration of dipyridamole, iNO could be stopped without rebound of PHT, and the neonate was extubated 1 week later. The authors report the use of dipyridamole for successful withdrawal of iNO. By inhibition of phosphodiesterase type 5, dipyridamole has the potential to increase the level of cyclic guanosine monophosphate in vascular smooth muscle cells, permitting vasodilation and restoration of endogenous NO. J Pediatr Surg 36:1864-1865.
Buysse
C
C
Paediatric Intensive Care Unit, Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles, Brussels, Belgium.
Fonteyne
C
C
Dessy
H
H
De Laet
M H
MH
Biarent
D
D
D004176:Dipyridamole / Q000008:administration & dosage* / Q000627:therapeutic use; D015199:Extracorporeal Membrane Oxygenation / Q000379:methods; D006548:Hernia, Diaphragmatic / Q000601:surgery; D065630:Hernias, Diaphragmatic, Congenital; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000517:prevention & control; D007231:Infant, Newborn; D009569:Nitric Oxide / Q000008:administration & dosage*; D012121:Respiration, Artificial / Q000379:methods*; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D015300:Ventilator Weaning / Q000379:methods*
D014665:Vasodilator Agents; D009569:Nitric Oxide; D004176:Dipyridamole